scholarly article | Q13442814 |
P356 | DOI | 10.1056/NEJM199504063321403 |
P698 | PubMed publication ID | 7877648 |
P50 | author | Paul Ridker | Q7153226 |
Meir J. Stampfer | Q80164992 | ||
Charles H Hennekens | Q89527500 | ||
P2093 | author name string | Miletich JP | |
Lindpaintner K | |||
Eisenberg PR | |||
P433 | issue | 14 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | thrombosis | Q261327 |
myocardial infarction | Q12152 | ||
P304 | page(s) | 912-917 | |
P577 | publication date | 1995-04-01 | |
P1433 | published in | The New England Journal of Medicine | Q582728 |
P1476 | title | Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men | |
P478 | volume | 332 |
Q34388472 | 1998 ASHG presidential address. Making genomic medicine a reality |
Q35024990 | A multilocus genotyping assay for candidate markers of cardiovascular disease risk |
Q40718658 | A prospective evaluation of the CD14 C(-260)T gene polymorphism and the risk of myocardial infarction |
Q34117782 | A prospective study of TaqIB polymorphism in the gene coding for cholesteryl ester transfer protein and risk of myocardial infarction in middle-aged men. |
Q33538903 | APCR, factor V gene known and novel SNPs and adverse pregnancy outcomes in an Irish cohort of pregnant women |
Q35169691 | Acquired activated protein C resistance, thrombophilia and adverse pregnancy outcomes: a study performed in an Irish cohort of pregnant women |
Q36100026 | Activated Protein C Resistance Does Not Increase Risk for Recurrent Stroke or Death in Stroke Patients |
Q71154638 | Activated protein C and pulmonary embolism |
Q26865139 | Activated protein C anticoagulant system dysfunction and thrombophilia in Asia |
Q54167601 | Activated protein C resistance and graft occlusion after coronary artery bypass surgery |
Q54150362 | Activated protein C resistance and the factor V Leiden mutation in children with thrombosis. |
Q41248865 | Activated protein C resistance as a basis for venous thrombosis |
Q41417615 | Activated protein C resistance caused by factor V gene mutation: common coagulation defect in chronic venous leg ulcers? |
Q58320642 | Activated protein C resistance in childhood stroke |
Q35298277 | Activated protein C resistance in patients with central retinal vein occlusion |
Q54120223 | Activated protein C resistance in patients with peripheral vascular disease. |
Q43632787 | Activated protein C resistance in young African American patients with ischemic stroke |
Q41137636 | Activated protein C resistance: from phenotype to genotype and clinical practice. |
Q91877901 | Acute pulmonary thromboembolism caused by factor V Leiden mutation in South Korea: A case report |
Q28361651 | American College of Medical Genetics consensus statement on factor V Leiden mutation testing |
Q51546713 | An age-related decrease in factor V Leiden frequency among Polish subjects. |
Q33893199 | An electrochemical detection scheme for identification of single nucleotide polymorphisms using hairpin-forming probes |
Q78111674 | Arg506Gln mutation of the coagulation factor V gene not detected in Japanese pulmonary thromboembolism |
Q77299095 | Arterial thromboembolic events in patients with the factor V Leiden mutation |
Q74597665 | Assessment of genetic markers for coronary thrombosis: promise and precaution |
Q35602154 | Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies |
Q35777683 | Association between thrombotic risk factors and extent of fibrosis in patients with non-alcoholic fatty liver diseases |
Q35894772 | Association of factor V gene polymorphism with arteriovenous graft failure |
Q37273821 | Attempted replication of reported chronic obstructive pulmonary disease candidate gene associations |
Q54021331 | Basilar artery thrombosis in a child heterozygous for factor V Leiden mutation. |
Q50534991 | C677T MTHFR mutation and factor V Leiden mutation in patients with TIA/minor stroke: a case-control study. |
Q54595795 | Characterisation of single nucleotide polymorphisms in sugarcane ESTs. |
Q35103077 | Clinical and laboratory evaluation of thrombophilia |
Q35291832 | Clinical significance of gene-diagnosis for defects in coagulation factors and inhibitors |
Q71691177 | Clinical significance of the FV:Q506 mutation in unselected oncology patients |
Q43587450 | Coexistence of thrombophilic gene polymorphisms among 559 unrelated consecutive patients with a history of thrombosis. |
Q43633269 | Correlation of polymorphisms to coagulation and biochemical risk factors for cardiovascular diseases |
Q38482800 | Decreased mortality of ischaemic heart disease among carriers of haemophilia |
Q81584045 | Deep vein thrombosis |
Q78171123 | Deep-vein thrombosis |
Q45108556 | Detection of a common mutation in factor V gene responsible for resistance to activate protein C causing predisposition to thrombosis. |
Q33655220 | Diagnosis and management of inherited and acquired thrombophilias |
Q33886973 | Diagnostic evaluation of stroke |
Q34027225 | Duration and intensity of anticoagulation among patients with genetic predispositions to venous thrombosis |
Q50854569 | Effect of anticoagulant therapy on the hypercoagulable state in patients carrying the factor V Arg506Gln mutation. |
Q54079422 | Effect of exogenous estrogen on atherothrombotic vascular disease risk related to the presence or absence of the factor V Leiden mutation (resistance to activated protein C). |
Q34990662 | Effects of lipids on thrombotic mechanisms in atherosclerosis |
Q86494328 | Elevated lipoprotein(a) levels and homozygous human platelet antigen 1b (HPA-1b) genotype are risk factors for intrauterine growth restriction (IUGR) |
Q35019234 | Elevated risk of thrombophilia in agenesis of the vena cava as a factor for deep vein thrombosis. |
Q47889309 | Emerging risk factors for stroke: patent foramen ovale, proximal aortic atherosclerosis, antiphospholipid antibodies, and activated protein C resistance |
Q37723948 | Establishment of a model of spontaneously-running-Tokushima-shikoku rats with left atrial thrombosis |
Q34065857 | Etiology and pathophysiology of stroke as a complex trait |
Q34439986 | Evaluation of GenoFlow Thrombophilia Array Test Kit in its detection of mutations in Factor V Leiden (G1691A), prothrombin G20210A, MTHFR C677T and A1298C in blood samples from 113 Turkish female patients |
Q73295929 | Evaluation of Hypercoagulable States |
Q38471289 | Evaluation of role of factor V Leiden mutation in fatal pulmonary thromboembolism |
Q47583371 | Evaluation of temperature gradient capillary electrophoresis for detection of the Factor V Leiden mutation: coincident identification of a novel polymorphism in Factor V. |
Q54160830 | Evidence against heterozygous coagulation factor V 1691 G-->A mutation with resistance to activated protein C being a risk factor for coronary artery disease and myocardial infarction. |
Q36253998 | Exacerbated venous thromboembolism in mice carrying a protein S K196E mutation |
Q47686776 | FV-ARG-506-GLN-Mutation-associated resistance to activated protein C in ischemic stroke |
Q71807450 | Factor V Leiden and Risks of Recurrent Idiopathic Venous Thromboembolism |
Q44461414 | Factor V Leiden and prothrombin gene G20210A mutations in ocular Behçet disease |
Q46136302 | Factor V Leiden and risk of ischemic stroke in nonvalvular atrial fibrillation: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study |
Q36147640 | Factor V Leiden is associated with higher risk of deep venous thrombosis of large blood vessels |
Q33543425 | Factor V Leiden mutation: a nursing perspective |
Q33606504 | Factor V Leiden: should all women be screened prior to commencing the contraceptive pill? |
Q36600956 | Factor V Leiden: should we screen oral contraceptive users and pregnant women? |
Q74020811 | Factor V R506Q mutation-Leiden: an independent risk factor for venous thrombosis but not coronary artery disease |
Q37041027 | Factor VLeiden and prothrombin G20210A gene polymorphisms in patients with coronary artery disease |
Q44683596 | Factor Va is inactivated by activated protein C in the absence of cleavage sites at Arg-306, Arg-506, and Arg-679. |
Q73384826 | Factors V leiden and II 20210A in patients with symptomatic pulmonary embolism and deep vein thrombosis |
Q36539672 | Functional single nucleotide polymorphism-based association studies |
Q73386872 | G20210A mutation in the prothrombin gene and the risk of recurrent venous thromboembolism |
Q41245762 | General internal medicine update. Information clinicians and teachers need to know |
Q53967904 | Genetic analysis of factor V Leiden in a family with history of thrombosis and venous leg ulcers. |
Q44823742 | Genetic and acquired thrombotic factors in chronic hepatitis C. |
Q52211005 | Genetic determinants of heritable venous thrombosis: genotyping methods for factor V(Leiden)A1691G, methylenetetrahydrofolate reductase C677T, prothrombin G20210A mutation, and algorithms for venous thrombosis investigations. |
Q49289901 | Genetic thrombophilia in patients with retinal vascular occlusion |
Q35532628 | Genetics and pulmonary medicine. 4. Pulmonary embolism |
Q41725452 | Genetics of stroke--a review |
Q22306331 | Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association |
Q37274431 | Hematological diseases and stroke |
Q28195599 | Hemostatic markers with bolus versus prolonged heparin after carotid artery stenting |
Q41615867 | Hemostatic risk factors in arterial thrombosis and atherosclerosis: the thrombin-fibrin and platelet-vWF axis |
Q39405390 | Hereditary risk factors for thrombophilia and probability of venous thromboembolism during pregnancy and the puerperium |
Q77813840 | Heterozygosity for factor V Leiden and G20210A prothrombin genotypes in a patient with mesenteric vein thrombosis |
Q73925175 | Heterozygosity for the Leiden mutation of the factor V gene, a common pathoetiology for osteonecrosis of the jaw, with thrombophilia augmented by exogenous estrogens |
Q91672343 | High factor VIII levels and arterial thrombosis: illustrative case and literature review |
Q33835022 | High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. |
Q79293356 | Homozygous factor V Leiden mutation in a patient with traumatic leg ulceration |
Q47889299 | Homozygous hereditary resistance to activated protein C presenting as cerebral venous thrombosis |
Q33374342 | Hypercoagulability syndromes: what the dentist needs to know |
Q34755474 | Hypercoagulability test strategies in the protein C and protein S pathway |
Q37040260 | Hypercoagulable State |
Q36254845 | Hypercoagulable states and stroke: a selective review. |
Q36527933 | Hypercoagulable states and strokes |
Q73454568 | Impact of activated protein C resistance on general vascular surgical patients |
Q43631890 | Importance of hyperhomocysteinemia as a risk factor for venous thromboembolism in a Taiwanese population. A case-control study |
Q54069752 | Incidence of factor V Leiden in patients with acute myocardial infarction. |
Q57580952 | Incidence of venous thromboembolism in breast cancer patients during chemotherapy with vinorelbine, cisplatin, 5-fluorouracil as continuous infusion (ViFuP regimen): Is prophylaxis required? |
Q44823539 | Incidence, risk factors, and outcomes of central venous catheter-related thromboembolism in breast cancer patients: the CAVECCAS study. |
Q52995735 | Increased rate of factor V Leiden mutation in patients with cerebral venous thrombosis. |
Q57611907 | Influence of three potential genetic risk factors for thrombosis in 43 families carrying the factor V Arg 506 to Gln mutation |
Q36318902 | Inherited prothrombotic states and ischaemic stroke in childhood |
Q73374027 | Inherited risk factors for venous thromboembolism: Implications for clinical practice |
Q33912473 | Inherited risk factors for venous thromboembolism: implications for clinical practice |
Q73643174 | Inherited thrombophilia: memorandum from a joint WHO/International Society on Thrombosis and Haemostasis meeting |
Q43015923 | Internal medical investigations for non-arteritic retinal artery occlusion |
Q50749619 | Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial. |
Q93149736 | Isolated pulmonary embolism in a patient with progestin intrauterine device and factor V Leiden |
Q33181978 | Joint effect of G1691A factor V point mutation and factor VII Arg/Gln(353) gene polymorphism on the risk of premature coronary artery disease |
Q77919943 | Laboratory evaluation of hypercoagulable states |
Q37638524 | Late failure of a split-thickness skin graft in the setting of homozygous factor V Leiden mutation: a case report and correlative animal model from the Wound Etiology and Healing (WE-HEAL) study |
Q52594205 | Latest Innovations in the Treatment of Venous Disease. |
Q75211795 | Liver transplantation in a patient with Budd-Chiari syndrome secondary to factor V Leiden mutation |
Q33798485 | Longitudinal assessment of fibrinogen in relation to subclinical cardiovascular disease: the CARDIA study |
Q44870490 | MTHFR C677T polymorphism and its relation to ischemic stroke in the Black Sea Turkish population |
Q77312905 | Multiple hemostatic abnormalities in young adults with activated protein C resistance and cerebral ischemia |
Q72000277 | Mutation in the Factor V Gene and the Risk of Myocardial Infarction |
Q38760099 | Myocardial infarction and future risk of cancer in the general population-the Tromsø Study. |
Q74079066 | Myocardial infarction in a 35-year-old man with homocysteinemia, high plasminogen activator inhibitor activity, and resistance to activated protein C |
Q34180939 | Myocardial infarction in patients with normal coronary arteries: proposed pathogenesis and predisposing risk factors |
Q48985896 | Neonatal purpura fulminans in association with factor V R506Q mutation |
Q73295920 | No Prognostic Importance of Resistance to Activated Protein C in Unstable Coronary Artery Disease Despite Signs of Thrombin Activation |
Q47820580 | No association between factor V Leiden mutation and coronary heart disease or carotid intima media thickness: the NHLBI Family Heart Study |
Q71158541 | Nonconsensual participation in genetic studies |
Q58491249 | Ocular involvement in primary antiphospholipid syndrome. Ocular involvement in primary APS |
Q77093727 | Oral contraceptives and arterial and venous thrombosis: a clinician's formulation |
Q52951935 | Overestimation of genetic risks owing to small sample sizes in cardiovascular studies. |
Q73073912 | PIA1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis |
Q44073454 | Paradoxical embolism causing acute embolic events in a patient with hereditary thrombophilia |
Q36954967 | Patent foramen ovale and hypercoagulability as combined risk factors for stroke |
Q40813736 | Pediatric Thromboembolism in Japan |
Q21144940 | Phased whole-genome genetic risk in a family quartet using a major allele reference sequence |
Q36840306 | Plasma resistance to activated protein C regulates the activation of coagulation induced by thrombolysis in patients with ischaemic heart disease |
Q33635802 | Platelet-dependent and procoagulant mechanisms in arterial thrombosis. |
Q39547196 | Polymorphisms in Factor II and Factor V thrombophilia genes among Circassians in Jordan |
Q35085299 | Polymorphisms in coagulation factor genes and their impact on arterial and venous thrombosis |
Q34477685 | Polymorphisms in thrombophilia and renin-angiotensin system pathways, preterm delivery, and evidence of placental hemorrhage |
Q70913456 | Population study of the G1691A mutation (R506Q, FV Leiden) in the human factor V gene that is associated with resistance to activated protein C |
Q35692012 | Premature coronary artery disease: clinical risk factors and prognosis |
Q90669073 | Prevalence and Outcomes of Thrombophilia in Patients with Acute Pulmonary Embolism |
Q33739962 | Prevalence and outcome of activated protein C resistance in patients after peripheral arterial bypass grafts |
Q35369291 | Prevalence of factor V Leiden (APCR) and other inherited thrombophilias in young patients with myocardial infarction and normal coronary arteries |
Q74315449 | Prevalence of factor V Leiden and prothrombin variant G20210A in patients age <50 years with no significant stenoses at angiography three to four weeks after myocardial infarction |
Q34712722 | Prevalence of factor V Leiden in a Canadian blood donor population |
Q33618227 | Prevalence of the factor V Leiden mutation in hepatic and portal vein thrombosis |
Q73276117 | Prevalence of three prothrombotic polymorphisms. Factor V G1691A, factor II G20210A and methylenetetrahydrofolate reductase (MTHFR) C 677T in Argentina. On behalf of the Grupo Cooperativo Argentino de Hemostasia y Trombosis |
Q40838962 | Prevalence of thrombophilic disorders in takotsubo patients: the (ThROmbophylia in TAkotsubo cardiomyopathy) TROTA study |
Q33857984 | Prevention of coronary heart disease. Part II. Secondary prevention, detection of subclinical disease, and emerging risk factors |
Q22306369 | Primary prevention of ischemic stroke |
Q28084640 | Progress in research into the genes associated with venous thromboembolism |
Q46715240 | Prothrombin G20210A and factor V Leiden polymorphisms in stroke |
Q47741045 | Prothrombotic coagulation defects and cardiovascular risk factors in young women with acute myocardial infarction |
Q35113270 | Prothrombotic determinants of coronary atherothrombosis |
Q28187014 | Prothrombotic gene polymorphisms and atherothrombotic cerebral infarction |
Q33347822 | Prothrombotic genetic risk factors and heparin-induced thrombocytopenia |
Q77397081 | Prothrombotic mutations as a risk factor for preterm birth |
Q71111882 | Pulmonary embolism and deep venous thrombosis during pregnancy or oral contraceptive use: prevalence of factor V Leiden |
Q35691663 | Racial differences in the prevalence of Factor V Leiden mutation among patients on chronic warfarin therapy |
Q53929962 | Reactions to awareness of activated protein C resistance carriership: a descriptive study of 270 women. |
Q36647304 | Recent trends in venous thrombosis and pulmonary embolism |
Q36589500 | Recurrent pregnancy loss in a subject with heterozygote factor V Leiden mutation; a case report |
Q38283515 | Recurrent venous thromboembolism in a patient with heterozygous factor v leiden mutation |
Q77357100 | Relative influence of age and thrombotic history on hemostatic parameters |
Q41161249 | Resistance to activated protein C and a novel factor V gene mutation. |
Q41714654 | Resistance to activated protein C and low levels of free protein S in Greek patients with inflammatory bowel disease |
Q77690865 | Resistance to activated protein C and the leiden mutation: high prevalence in patients with abruptio placentae |
Q71094424 | Resistance to activated protein C in an unselected population of patients with pulmonary embolism |
Q45882491 | Resistance to activated protein C in unselected patients with arterial and venous thrombosis |
Q34013076 | Resistance to activated protein C is a risk factor for fibrostenosis in Crohn's disease |
Q73236487 | Risk factors for venous thromboembolism |
Q36698661 | Risk of venous thromboembolism and myocardial infarction associated with factor V Leiden and prothrombin mutations and blood type |
Q77742224 | Risk reduction in the intensive care unit |
Q44556178 | Role of factor V Leiden and prothrombin 20210A in patients with retinal artery occlusion |
Q77169209 | Role of factor V Leiden mutation in patients with angiographically demonstrated coronary artery disease |
Q34573328 | Role of investigating thrombophilic disorders in young stroke. |
Q58622092 | Résistance à la protéine C activée et thrombose portale: deux nouveaux cas et revue de la littérature |
Q73886035 | Screening for resistance to activated protein C and the mutant gene for factor V:Q506 in patients with central retinal vein occlusion |
Q54051918 | Screening for risk factors for thrombosis using a new generation of assays developed to evaluate the functionality of the protein C anticoagulant pathway. |
Q74840852 | Sensitivity of the ProC global assay for protein C pathway abnormalities. clinical experience in 899 unselected patients with venous thromboembolism |
Q28222847 | Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration |
Q33504430 | Streptococcus sanguis-induced platelet clotting in rabbits and hemodynamic and cardiopulmonary consequences. |
Q54140056 | Stroke in a neonate heterozygous for factor V Leiden. |
Q63544748 | Sudden Infant Death Syndrome, Childhood Thrombosis, and Presence of Genetic Risk Factors for Thrombosis |
Q42089515 | Superior sagittal sinus and inferior vena cava thrombosis with acute Budd-Chiari syndrome |
Q47913521 | The Arg506Gln mutation (FV Leiden) among a cohort of 4188 unselected Danish newborns |
Q52131991 | The Association of Anticoagulant Protein Concentrations with Acute Myocardial Infarction in the Thromholysis in Myocardial Infarction Phase II (TIMI II) Trial. |
Q35087733 | The Association of Coagulation Factor V (Leiden) and Factor II (Prothrombin) Mutations With Stroke |
Q24794936 | The Ischemic Stroke Genetics Study (ISGS) Protocol |
Q37186133 | The Obstetric Medicine Listserv: review of controversies surrounding thrombophilia testing |
Q24803218 | The Siblings With Ischemic Stroke Study (SWISS) protocol |
Q42919824 | The association of protein S Tokushima-K196E with a risk of deep vein thrombosis |
Q74187715 | The decanucleotide polymorphism in the factor VII promoter predicts factor VII plasma levels but not the risk of acute coronary syndromes |
Q43598571 | The factor V Leiden mutation increases the risk of venous thrombosis in patients with inflammatory bowel disease |
Q73114776 | The factor V Leiden mutation: spectrum of thrombotic events and laboratory evaluation |
Q33685763 | The influence of developmental haemostasis on the laboratory diagnosis and management of haemostatic disorders during infancy and childhood. |
Q73485462 | The prevalence of two genetic traits related to venous thrombosis in whites and African-Americans |
Q34971549 | Three periods of one and a half decade of ischemic stroke susceptibility gene research: lessons we have learned |
Q35784744 | Thrombophilia Associated with Anti-DFS70 Autoantibodies |
Q34043661 | Thrombophilia in pregnancy |
Q33773160 | Thrombophilia-associated pregnancy wastage |
Q33636714 | Thrombophilia: disorders predisposing to venous thromboembolism |
Q77664583 | Thrombophilic disorders in children with cerebral infarction |
Q90056535 | Treating Venous Thromboembolism Post Intracranial Hemorrhage: A Case Report |
Q73851835 | Two common genetic thrombotic risk factors: factor V Leiden and prothrombin G20210A in adult Turkish patients with thrombosis |
Q36751693 | Vasa vitae--keeping the channels open |
Q33950366 | Vascular risk factors for Alzheimer's disease: an epidemiologic perspective. |
Q47993392 | Venous thromboembolism hospitalizations among American Indians and Alaska Natives |
Q54077386 | Venous thromboembolism, factor V Leiden, and methylenetetrahydrofolate reductase in a sickle cell anemia patient. |
Q32151734 | Will genetics really revolutionize the drug discovery process? |
Q34057587 | World distribution of factor V Leiden |
Q70811527 | World distribution of factor V Leiden mutation |
Q78006813 | [Angiology update] |
Q81153272 | [Cerebral infarction of arterial origin and haematological causation: the Lausanne experience and a review of the literature] |
Q78724057 | [Cerebral-vein thrombosis: retrospective study of twenty seven cases] |
Q79954729 | [Chronic abdominal pain due to bowel ischemia in a patient with Leiden factor V mutation] |
Q74339763 | [Coronary thrombosis on patient with the factor V Leiden mutation] |
Q78066774 | [Current suspect and diagnosis of pulmonary thromboembolism] |
Q53919688 | [Factor V Leiden and myocardial infarction: a case, review of the literature with a meta-analysis]. |
Q79210246 | [Homocysteinemia and thrombophilic factors in unexplained decompression sickness] |
Q74353796 | [New causes of inherited thrombophilia] |
Search more.